Lineage Cell Therapeutics, Inc. Equity Method Investments
Lineage Cell Therapeutics, Inc. (LCTX) had Equity Method Investments of $87.31 million as of 2017-03-31, per its 10-Q filed 2017-05-10.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Long-Term Investments and Receivables, Net
us-gaap:EquityMethodInvestments · last filed 2017-05-10
- 2017-03-31: Equity Method Investments $87.31M.
- 2016-12-31: Equity Method Investments $0.00.
- 2016-09-30: Equity Method Investments $3.48M.
- 2016-06-30: Equity Method Investments $4.34M.
| Period end | Equity Method Investments |
|---|---|
| 2017-03-31 | $87.31M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $0.00 10-Q · filed 2017-05-10 |
| 2016-09-30 | $3.48M 10-Q · filed 2016-11-04 |
| 2016-06-30 | $4.34M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $4.44M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $4.67M 10-K · filed 2017-03-16 |
| 2014-12-31 | $0.00 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |